New York, United States
Inspirna, Inc., a privately-held clinical-stage biopharmaceutical company founded in 2010, is pioneering advancements in oncology by transforming cancer into a manageable, chronic condition. Headquartered in the United States, the company focuses on discovering and developing groundbreaking cancer drugs aimed at critical pathways in high unmet need cancers.
Their lead candidate, ompenaclid (RGX-202), targets the CKB/SLC6A8 pathway and is undergoing mid-stage trials for RAS mutant colorectal cancer. A second candidate, abequolixron (RGX-104), is in a Phase 1b/2 trial for lung and endometrial cancer, in partnership with Bristol Myers Squibb.
Leveraging a proprietary discovery platform, RNA-DRIVEr, Inspirna identifies novel cancer targets. The company recently secured a $55.10M Series D investment on 11 July 2022, backed by Novo Holdings, Sofinnova Partners, Vivo Capital, and others, highlighting strong investor confidence and future potential in the competitive Biotechnology space.
